NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) and Spacelabs Healthcare Clinical Trial Services today announced a partnership to offer Clinical Data’s proprietary services related to the testing of drug-induced QT prolongation to Spacelabs’ customers through Clinical Data’s service division, Cogenics™. This agreement will assist drug development researchers and governmental regulatory agencies in improving the utility of the trials in detecting or ruling out meaningful QT prolonging effects by controlling for genetic variables. The pharmacogenomics analyses will be performed at the New Haven, Conn. laboratories of Clinical Data.
